Old Web
English
Sign In
Acemap
>
Paper
>
Eculizumab discontinuation in atypical hemolytic uremic syndrome: TMA recurrence risk and renal outcomes
Eculizumab discontinuation in atypical hemolytic uremic syndrome: TMA recurrence risk and renal outcomes
2021
Gema Ariceta
Fadi Fakhouri
Lisa Sartz
Benjamin Miller
Vasilis Nikolaou
David J. Cohen
Andrew M. Siedlecki
Gianluigi Ardissino
Keywords:
Internal medicine
Medicine
Eculizumab
Atypical hemolytic uremic syndrome
Discontinuation
Gastroenterology
recurrence risk
Correction
Source
Cite
Save
Machine Reading By IdeaReader
30
References
0
Citations
NaN
KQI
[]